Latest filingSep 03, 2026Most recent Form 4
STOK
Stoke Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$81.6M8 sells
Net open-market-$81.6M3 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period14transactions
- S · Open-market sells · dominant8 · 57%
- M · Option exercise6 · 43%
Activity by reported role
A joint filing can contribute to multiple roles18transactions
- CMO · dominant6 · 33%
- CS4 · 22%
- Director4 · 22%
- GC4 · 22%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (3)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeTicho BarryCommon Stock · Direct
20,110Sep 01, 2026
Allan JonathanCommon Stock · Direct
21,225Aug 18, 2026
Kaye Edward M. MDCommon Stock · Direct
125,194Aug 18, 2026
Allan JonathanPerformance Stock Units · Direct
0Aug 14, 2026
Kaye Edward M. MDPerformance Stock Units · Direct
0Aug 14, 2026
Ticho BarryPerformance Stock Units · Direct
0Aug 14, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 04 → Sep 04
LessMore
Top insiders
By absolute net value across the selected period- TB-$170.1k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
STOK transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| STOK | Ticho Barry | CMO | sale10b5-1 | 1.60k | -$4.96M | S | — | 0.0% | 09/03 | 09/01 |
| STOK | Ticho Barry | CMO | sale10b5-1 | 3.94k | -$12.0M | S | — | 0.0% | 09/03 | 09/01 |
Stoke Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Stoke Therapeutics, Inc.?
Ticho Barry, Kaye Edward M. MD, Allan Jonathan.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Ticho Barry reported a sale on Sep 01, 2026 valued at $4.96M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $816,918.25. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.